Eleven Biotherapeutics Inc. (Nasdaq: EBIO) will receive a $22.5 million milestone payment from F. Hoffmann-La Roche and Hoffman-La Roche after the company's Investigational New Drug application for EBI-031 became effective. Shares of the biopharmaceutical gained 52 cents to close at $2.48.
Eleven Biotherapeutics to receive milestone payment
July 08, 2016 at 17:03 PM EDT
